AZILECT Drug Patent Profile
✉ Email this page to a colleague
When do Azilect patents expire, and what generic alternatives are available?
Azilect is a drug marketed by Teva and is included in one NDA. There are two patents protecting this drug.
This drug has twenty-six patent family members in eighteen countries.
The generic ingredient in AZILECT is rasagiline mesylate. There are eighteen drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the rasagiline mesylate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Azilect
A generic version of AZILECT was approved as rasagiline mesylate by ORBION PHARMS on March 15th, 2016.
Summary for AZILECT
| International Patents: | 26 |
| US Patents: | 2 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 3 |
| Raw Ingredient (Bulk) Api Vendors: | 212 |
| Clinical Trials: | 27 |
| Patent Applications: | 5,218 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for AZILECT |
| What excipients (inactive ingredients) are in AZILECT? | AZILECT excipients list |
| DailyMed Link: | AZILECT at DailyMed |
Recent Clinical Trials for AZILECT
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| National Institute of Neurological Disorders and Stroke (NINDS) | Phase 2 |
| University of Florida | Phase 2 |
| Thomas Guttuso |
Pharmacology for AZILECT
| Drug Class | Monoamine Oxidase Inhibitor |
| Mechanism of Action | Monoamine Oxidase Inhibitors |
Anatomical Therapeutic Chemical (ATC) Classes for AZILECT
US Patents and Regulatory Information for AZILECT
AZILECT is protected by two US patents.
Patents protecting AZILECT
Rasagiline formulations and processes for their preparation
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Rasagiline formulations of improved content uniformity
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF PARKINSON'S DISEASE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Teva | AZILECT | rasagiline mesylate | TABLET;ORAL | 021641-001 | May 16, 2006 | AB | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | |
| Teva | AZILECT | rasagiline mesylate | TABLET;ORAL | 021641-002 | May 16, 2006 | AB | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||
| Teva | AZILECT | rasagiline mesylate | TABLET;ORAL | 021641-001 | May 16, 2006 | AB | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for AZILECT
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Teva | AZILECT | rasagiline mesylate | TABLET;ORAL | 021641-002 | May 16, 2006 | ⤷ Try a Trial | ⤷ Try a Trial |
| Teva | AZILECT | rasagiline mesylate | TABLET;ORAL | 021641-001 | May 16, 2006 | ⤷ Try a Trial | ⤷ Try a Trial |
| Teva | AZILECT | rasagiline mesylate | TABLET;ORAL | 021641-002 | May 16, 2006 | ⤷ Try a Trial | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for AZILECT
See the table below for patents covering AZILECT around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| China | 1096853 | ⤷ Try a Trial | |
| Japan | H11512736 | ⤷ Try a Trial | |
| Portugal | 812190 | ⤷ Try a Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for AZILECT
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0812190 | SPC024/2005 | Ireland | ⤷ Try a Trial | SPC024/2005, 20060725, EXPIRES: 20191011 |
| 0436492 | CA 2005 00040 | Denmark | ⤷ Try a Trial | |
| 0812190 | 300205 | Netherlands | ⤷ Try a Trial | 300205, 20141012, EXPIRES: 20191011 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2023 - 2024
NCE-1 Patent Challenge Dates 2023 - 2024
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2023, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
